

**etanercept 50mg subcutaneous injection (Enbrel<sup>®</sup>)  
for psoriatic arthritis  
Wyeth Pharmaceuticals**

**No. (304/06)**

**Product Update – New Formulation**

4 August 2006 (*issued September 2006*)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**etanercept 50mg subcutaneous injection (Enbrel<sup>®</sup>)** is accepted for use within NHS Scotland for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate.

Etanercept improves the symptoms of arthritis and psoriasis and may slow the progression of joint damage (at least over a period of one year). The 50mg formulation facilitates once weekly administration of etanercept at no additional cost over the existing 25mg formulation that is administered twice weekly.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 22 August 2006.*

**Chairman, Scottish Medicines Consortium**